EU agency says blood clot ‘rare’ J&J side effect
The Hindu
It believes benefits outweigh risks
Europe’s medicines regulator said on Tuesday that blood clots should be listed as a “very rare” side effect of Johnson & Johnson’s vaccine, but that the benefits of the shot still outweigh the risks. The United States is also expected to announce its decision on the single-shot J&J vaccine by Friday, as nations around the world urgently try to accelerate inoculation campaigns and revive their pandemic-ravaged economies. The European Medicines Agency (EMA) assessment came as an EU official promised to have enough doses available to vaccinate 70% of European adults by the summer — a boon for the continent’s sluggish rollout.More Related News

Former CM B.S. Yediyurappa had challenged the first information report registered on March 14, 2024, on the alleged incident that occurred on February 2, 2024, the chargesheet filed by the Criminal Investigation Department (CID), and the February 28, 2025, order of taking cognisance of offences afresh by the trial court.